Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Therapeutic realities and possibilities

被引:163
作者
Michel, M [1 ]
Gutmann, L [1 ]
机构
[1] HOP BROUSSAIS,MICROBIOL LAB,F-75674 PARIS 14,FRANCE
关键词
D O I
10.1016/S0140-6736(96)11192-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During the past decade much effort has been devoted worldwide to limiting the spread of methicillin-resistant Staphylococcus aureus. However, the recent emergence of almost untreatable vancomycin-resistant enterococci has led to a new and unexpected public health problem in hospitals and the community. Moreover, the threat of transfer of glycopeptide resistance to S aureus means that development of alternative antimicrobial strategies has become urgent. Whereas major advances have been made in our understanding of methicillin and vancomycin resistance mechanisms, we still need to identify the sources and reservoirs of the genetic determinants of resistance and to discover how they disseminate in the environment. The outcome of the battle between antimicrobials and bacteria is still uncertain, but the challenge is worth meeting.
引用
收藏
页码:1901 / 1906
页数:6
相关论文
共 62 条
[21]   Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): A report of fifteen cases [J].
Dever, LL ;
Smith, SM ;
Dejesus, D ;
Masurekar, M ;
Patel, D ;
Kaminski, ZC ;
Johanson, WG .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1996, 2 (04) :407-413
[22]   TREATMENT OF EXPERIMENTAL ENDOCARDITIS DUE TO ERYTHROMYCIN-SUSCEPTIBLE OR ERYTHROMYCIN-RESISTANT METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS WITH RP-59500 [J].
ENTENZA, JM ;
DRUGEON, H ;
GLAUSER, MP ;
MOREILLON, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1419-1424
[23]   FUSIDIC ACID ALONE OR IN COMBINATION WITH VANCOMYCIN FOR THERAPY OF EXPERIMENTAL ENDOCARDITIS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
FANTIN, B ;
LECLERCQ, R ;
DUVAL, J ;
CARBON, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2466-2469
[24]  
FANTIN B, 1994, ANTIMICROB AGENTS SA, V30, P29
[25]  
FINLAND M, 1979, REV INFECT DIS, V1, P4
[26]   In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections [J].
Ford, CW ;
Hamel, JC ;
Wilson, DM ;
Moerman, JK ;
Stapert, D ;
Yancey, RJ ;
Hutchinson, DK ;
Barbachyn, MR ;
Brickner, SJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1508-1513
[27]   IN-VITRO ACTIVITY OF 2 GLYCYLCYCLINES AGAINST ENTEROCOCCI RESISTANT TO OTHER AGENTS [J].
FRAISE, AP ;
BRENWALD, N ;
ANDREWS, JM ;
WISE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (06) :877-881
[28]   BETA-LACTAM RESISTANCE MECHANISMS OF METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
FRANCIOLLI, M ;
BILLE, J ;
GLAUSER, MP ;
MOREILLON, P .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (03) :514-523
[29]   SYNERGY AND RESISTANCE TO SYNERGY BETWEEN BETA-LACTAM ANTIBIOTICS AND GLYCOPEPTIDES AGAINST GLYCOPEPTIDE-RESISTANT STRAINS OF ENTEROCOCCUS-FAECIUM [J].
GUTMANN, L ;
ALOBEID, S ;
BILLOTKLEIN, D ;
GUERRIER, ML ;
COLLATZ, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :824-829
[30]  
HACKBARTH CJ, 1994, ANTIMICROB AGENTS CH, V38, P447